GSK ends long-running work targeting NY-ESO-1, and that’s bad news for Adaptimmune as well as Lyell.
But can the novel antigen be targeted effectively? Immatics reckons it can, with the right dose and the right manufacturing process.
Inhibition of Kras dominated Esmo, though probably not in the way some had hoped.
February will also see an outcome for Gilead's long-acting HIV therapy, and a key FDA panel for me-too checkpoint MAbs.
Leap and Innate were clear winners on the stock market during the medical meeting, while Astrazeneca’s strong performance stands out among the large caps.
A low-key cancer discovery alliance sees Roche abandoning its earlier opposition to cell therapies.